AstraZeneca COVID-19 vaccine and Guillain- Barr acute accent e Syndrome in Tasmania: A causal link?

被引：43

作者：

Oo, Wai M. ^{[1
,2
,3
]}

Giri, Pradeep ^{[1
,4
]}

de Souza, Aaron ^{[2
,3
]}

机构：

[1] Launceston Gen Hosp, Dept Med, 274-280 Charles St, Launceston, Tas 7250, Australia

[2] Launceston Gen Hosp, Dept Neurol, Launceston, Tas, Australia

[3] Univ Tasmania, Fac Med, Launceston, Tas, Australia

[4] Launceston Gen Hosp, Dept Infect Dis, Launceston, Tas, Australia

来源：

JOURNAL OF NEUROIMMUNOLOGY | 2021年 / 360卷

关键词：

Guillain-Barre syndrome; Inflammatory demyelinating polyneuropathy; COVID-19; AstraZeneca vaccine; vaccine; Chronic inflammatory demyelinating; polyneuropathy (CIDP); DIAGNOSIS; CRITERIA; PATHOGENESIS; INFECTION;

D O I：

10.1016/j.jneuroim.2021.577719

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The emergence of the coronavirus 2019 (COVID-19) pandemic has presented an unprecedented global challenge. Vaccines against COVID have been developed to date. Covid-19 has been linked with the development of Guillain-Barre Syndrome (GBS), a rare immune-mediated demyelinating neuropathy. We report three cases of Guillain-Barre Syndrome and one case of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), presenting to a Tasmanian hospital, and review 15 other reported cases and discuss likely immunopathology. Nearly all reported cases of post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to AstraZeneca vaccination and a variant with bifacial weakness is the most reported form of GBS globally.

引用

页数：5

共 37 条

[1] Guillain-Barre Syndrome Variant Occurring after SARS-CoV-2 Vaccination [J].

Allen, Christopher Martin ;

Ramsamy, Shelby ;

Tarr, Alexander William ;

Tighe, Patrick Jason ;

Irving, William Lucien ;

Tanasescu, Radu ;

Evans, Jonathan Rhys .

ANNALS OF NEUROLOGY, 2021, 90 (02) :315-318

[2] Characteristics, incidence and outcome of patients admitted to intensive care unit with Guillain-Barre syndrome in Australia and New Zealand [J].

Ancona, Paolo ;

Bailey, Michael ;

Bellomo, Rinaldo .

JOURNAL OF CRITICAL CARE, 2018, 45 :58-64

[3]

[Anonymous], Mali-COVID-19 Overview

[4] ASSESSMENT OF CURRENT DIAGNOSTIC-CRITERIA FOR GUILLAIN-BARRE-SYNDROME [J].

ASBURY, AK ;

CORNBLATH, DR .

ANNALS OF NEUROLOGY, 1990, 27 :S21-S24

[5]

Azam S., 2021, Am J Med Case Rep, V9, P424

[6] COVID-19-associated Guillain-Barresyndrome: The early pandemic experience [J].

Caress, James B. ;

Castoro, Ryan J. ;

Simmons, Zachary ;

Scelsa, Stephen N. ;

Lewis, Richard A. ;

Ahlawat, Aditi ;

Narayanaswami, Pushpa .

MUSCLE & NERVE, 2020, 62 (04) :485-491

[7] Advances in the diagnosis, pathogenesis and treatment of CIDP [J].

Dalakas, Marinos C. .

NATURE REVIEWS NEUROLOGY, 2011, 7 (09) :507-517

[8] Diagnosis of Guillain-Barre syndrome and validation of Brighton criteria [J].

Fokke, Christiaan ;

van den Berg, Bianca ;

Drenthen, Judith ;

Walgaard, Christa ;

van Doorn, Pieter Antoon ;

Jacobs, Bart Casper .

BRAIN, 2014, 137 :33-43

[9]

Hasan T., 2021, BMJ CASE REP

[10] Effects of COVID-19 on the Nervous System [J].

Iadecola, Costantino ;

Anrather, Josef ;

Kamel, Hooman .

CELL, 2020, 183 (01) :16-+

← 1 2 3 4 →